Navigation Links
Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference
Date:6/5/2009

SUNNYVALE, Calif., June 5 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated disease and cancer, today announced that Glenn Rice, President and COO will present on Wednesday, June 10, at 11:30 a.m. ET at the 8th Annual Needham Life Sciences Conference taking place at the New York Palace Hotel.

There will be a live webcast of the presentation, which will be accessible through a link posted on the home page and investor relations section of the PCYC website. The webcast will be available for replay through June 26, 2009.

About Pharmacyclics

Pharmacyclics(R) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of immune mediated disease and cancer. The purpose of the company is to create a profitable business by generating income from products it develops, licenses and commercializes, either with one or several potential partners or alone as may best forward the economic interest of its stakeholders. The company endeavors to create novel, patentable, differentiated products that have the potential to significantly improve the standard of care in the markets it serves. Presently, Pharmacyclics has four product candidates in clinical development and two product candidates in pre-clinical development. It is Pharmacyclics' business strategy to establish collaborations with large pharmaceutical and biotechnology companies for the purpose of generating present and future income in exchange for adding to their product pipelines. Pharmacyclics strives to generate collaborations that allow it to retain valuable territorial rights and simultaneously fast forward the clinical development and commerci
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pharmacyclics Files Registration Statement for Rights Offering
2. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
3. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
4. Pharmacyclics Secures $5.0 Million in Debt Financing
5. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
6. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
7. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
8. Pharmacyclics Announces It Received Nasdaq Notification
9. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
10. Data for SemBioSys insulin to be presented at the American Diabetes Associations 69th Scientific Sessions
11. Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... DUBLIN , Sept. 18, 2014 ... addition of the "Global N-acetylcysteine Industry Report ... The Global N-acetylcysteine Industry Report 2014 is ... state of the global N-acetylcysteine industry. ... industry including definitions, classifications, applications and industry chain ...
(Date:9/18/2014)... TX (PRWEB) September 18, 2014 ... a FM-4910 listed material, to stay competitive in ... These high-performance materials ultimately impact product quality ... President and owner. , Established in 1980 in ... strong as many fabricators have left the business. ...
(Date:9/18/2014)...  Neogen Corporation (Nasdaq: NEOG ) announced ... with Merck Animal Health to market Neogen,s Igenity ® ... Dairy Heifer Program consists of genomic tests that offer ... of replacement dairy heifers. The genomic tests can be ... an excellent tool in the decision-making process for breeding ...
(Date:9/18/2014)... Sept. 18, 2014   Sigma-Aldrich Corporation ... has entered into a new gene editing partnership ... Vector Core. Under the partnership, Sigma-Aldrich will provide ... design consultation, and dedicated gene editing bioinformaticians. ... editing-based research at the U-M Medical School. One ...
Breaking Biology Technology:Global N-acetylcysteine Industry Report 2014 2Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2Merck Animal Health to market Neogen's dairy genomic program 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4
... 2011 Quest Diagnostics Incorporated (NYSE: DGX ) ... process of identifying a successor to Surya N. Mohapatra, Ph.D., ... has formed a search committee, engaged a leading executive recruitment ... Dr. Mohapatra has agreed to continue to serve ...
... 25, 2011 New England Research Institutes (NERI) today ... from the National Institutes of Health (NIH) for the ... (PHN). PHN is a multi-center clinical research network started ... Blood Institute (NHLBI) of the National Institutes of Health, ...
... SEATTLE, Oct. 25, 2011 Cell Therapeutics, Inc. ("CTI" or ... results for the third quarter ended September 30, 2011. ... Company as we move pixantrone one step closer to potential ... Bianco, M.D., CEO of Cell Therapeutics, Inc. "We believe the ...
Cached Biology Technology:Quest Diagnostics Initiates CEO Succession Process 2New England Research Institutes (NERI) Announces Additional $45M NIH Grant to Support the Pediatric Heart Network 2New England Research Institutes (NERI) Announces Additional $45M NIH Grant to Support the Pediatric Heart Network 3Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones 2Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones 3Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones 4Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones 5Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones 6
(Date:9/18/2014)... from McGill University and the Quebec government have ... Canadian Journal of Fisheries and Aquatic Sciences ... household cleansers, or industrial cleansers, to which they ... small size and buoyancy, they may readily pass ... global contaminant in the world,s oceans, but have ...
(Date:9/18/2014)... No matter how many times it,s demonstrated, ... communicating creatures. , But by using a ... radically alter their behavior to suit their population. ... them are present, and act accordingly. , Once ... it may change from innocuous to pathogenic, or ...
(Date:9/18/2014)... and creatively manipulate spoken language is unique to humans. ... million years of human evolution to make this possible ... gene we now have," says Wolfgang Enard, Professor of ... to understand the molecular biological basis of language Enard ... of his latest study, undertaken in collaboration with scientists ...
Breaking Biology News(10 mins):Microplastic pollution discovered in St. Lawrence River sediments 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3
... 2011 Neurotechnology , a provider of ... of MegaMatcher Accelerator 4.0 , the latest ... solution for high-volume, high-speed fingerprint and iris identification. ... enhanced fault tolerance and a new matching algorithm ...
... the Hawai,i Institute of Marine Biology (HIMB) have developed ... part of a hybrid web application titled GeoSymbio ... on symbiotic zooxanthellae called Symbiodinium which are ... other marine organisms like anemones, jellyfish, and corals. ...
... University of Maryland School of Medicine researchers have uncovered ... understanding cardiac arrhythmia and other heart muscle problems. Understanding ... open the door to new treatments. The study, published ... electrical impulses that coordinate contraction in heart and skeletal ...
Cached Biology News:Neurotechnology Releases MegaMatcher Accelerator 4.0 for National-scale Fingerprint and Iris Biometric Identification 2Neurotechnology Releases MegaMatcher Accelerator 4.0 for National-scale Fingerprint and Iris Biometric Identification 3Neurotechnology Releases MegaMatcher Accelerator 4.0 for National-scale Fingerprint and Iris Biometric Identification 4An online global map of coral and zooxanthellae data for climate change study is released 2An online global map of coral and zooxanthellae data for climate change study is released 3UM School of Medicine finds new pathway critical to heart arrhythmia 2UM School of Medicine finds new pathway critical to heart arrhythmia 3
Request Info...
... The integration of 2D polyacrylamide gel electrophoresis ... regarded as a core technology platform for ... power for complex samples limited only in ... small and large proteins. Quantitative image based ...
... Pfx DNA Polymerase is ideal for ... downstream applications such as cloning and ... by a proprietary enzyme preparation containing ... with proofreading (3'Cut Site5' exonuclease) activity. ...
... PLAU N-term Antibody This antibody is ... conjugated synthetic peptide selected within aa 50~150 ... supplied in PBS with 0.09% (W/V) sodium ... protein G column and eluted out with ...
Biology Products: